Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
GATA4 induces liver fibrosis regression by deactivating hepatic stellate cells
Noelia Arroyo, … , David A. Cano, Anabel Rojas
Noelia Arroyo, … , David A. Cano, Anabel Rojas
Published October 26, 2021
Citation Information: JCI Insight. 2021;6(23):e150059. https://doi.org/10.1172/jci.insight.150059.
View: Text | PDF
Research Article Cell biology Gastroenterology

GATA4 induces liver fibrosis regression by deactivating hepatic stellate cells

  • Text
  • PDF
Abstract

In response to liver injury, hepatic stellate cells activate and acquire proliferative and contractile features. The regression of liver fibrosis appears to involve the clearance of activated hepatic stellate cells, either by apoptosis or by reversion toward a quiescent-like state, a process called deactivation. Thus, deactivation of active hepatic stellate cells has emerged as a novel and promising therapeutic approach for liver fibrosis. However, our knowledge of the master regulators involved in the deactivation and/or activation of fibrotic hepatic stellate cells is still limited. The transcription factor GATA4 has been previously shown to play an important role in embryonic hepatic stellate cell quiescence. In this work, we show that lack of GATA4 in adult mice caused hepatic stellate cell activation and, consequently, liver fibrosis. During regression of liver fibrosis, Gata4 was reexpressed in deactivated hepatic stellate cells. Overexpression of Gata4 in hepatic stellate cells promoted liver fibrosis regression in CCl4-treated mice. GATA4 induced changes in the expression of fibrogenic and antifibrogenic genes, promoting hepatic stellate cell deactivation. Finally, we show that GATA4 directly repressed EPAS1 transcription in hepatic stellate cells and that stabilization of the HIF2α protein in hepatic stellate cells leads to liver fibrosis.

Authors

Noelia Arroyo, Laura Villamayor, Irene Díaz, Rita Carmona, Mireia Ramos-Rodríguez, Ramón Muñoz-Chápuli, Lorenzo Pasquali, Miguel G. Toscano, Franz Martín, David A. Cano, Anabel Rojas

×

Figure 5

GATA4 is a direct repressor of EPAS1 in HSCs.

Options: View larger image (or click on image) Download as PowerPoint
GATA4 is a direct repressor of EPAS1 in HSCs.
(A) Quantitative RT-PCR an...
(A) Quantitative RT-PCR analysis of EPAS1 expression in LX2 cells transfected with GFP-expressing (Ad-GFP) and GATA4-expressing (Ad-GATA4) adenoviruses (n = 3, Ad-GFP; n = 4, Ad-GATA4). (B) Quantitative RT-PCR analysis of EPAS1 expression in G2-Cre;Gata4 KO E13.5 embryonic liver (n = 5, control; n = 4, GATA4 KO). (C) Quantitative RT-PCR analysis of EPAS1 expression in livers of adult Gata4-floxed mice injected with GFP-expressing (Ad-GFP) (n = 4) and Cre-expressing adenoviruses (Ad-Cre) (n = 3). (D) Quantitative RT-PCR analysis in LX2 cells transfected with a siRNA directed against EPAS1 compared with control LX2 cells (treated with siRNA-negative control) (n = 3). (E) Schematic of the human EPAS1 intronic region containing 2 conserved GATA sites using Vista Tools software. The blue peak indicates the human EPAS1 transcription start, and the pink peaks indicate conserved noncoding regions between human and mouse. An 810 bp fragment of EPAS1 intronic region containing the 2 conserved GATA4 sites (EPAS1 wt) or the mutated version (EPAS1 mut) was cloned into the pGL3 luciferase vector for reporter assays. The nucleotides mutated in EPAS1 mut are shown in lowercase. The numbers indicate the localization in the EPAS1 locus from the transcriptional start site. (F) ChIP of LX2-overexpressing GATA4 using a GATA4-specific antibody or a IgG-unspecific antibody (n = 3). (G) In vitro luciferase reporter assays in 293T cells of pGL3-EPAS1 wt and pGL3-EPAS1 mut plasmids (n = 3). Statistical analyses was performed using 2-tailed Student’s test. Error bars represent mean ± SEM. *P < 0.05. RLU, relative light units.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts